INTRODUCTION {#s1}
============

POEMS syndrome, also called as Crow-Fukase syndrome or Takatsuki syndrome, is a rare paraneoplastic syndrome characterized by polyneuropathy, organomegaly, endocrinopathy, mono-clonal gammopathy, and skin changes \[[@R1], [@R2]\]. It's associated with an underlying clonal plasma cell dyscrasia \[[@R1], [@R2]\]. Other important manifestations include Castleman's disease, sclerotic bone lesions, papilledema, thrombocytosis, polycythemia, extravascular volume overload, pulmonary hypertension, clubbing, weight loss, thrombotic diatheses and vitamin B12 deficiency \[[@R1], [@R3], [@R4]\]. Although the pathogenesis of POEMS syndrome is still unclear, the overproduction of vascular endothelial growth factor (VEGF), as one of the major diagnostic criteria of POEMS syndrome \[[@R1]\], may contribute to most of the above clinical manifestations and correlates with the disease activity and response to therapy \[[@R5], [@R6]\]. VEGF targets vessel endothelial cell by increasing vascular permeability and promoting angiogenesis \[[@R7]-[@R9]\], which may result in arterial or venous thrombosis \[[@R10], [@R11]\]. Recently, ischemic stroke is attracting increasing attention as a less-recognized manifestation of POEMS syndrome and its 5-years risk is reported to be 13.4% \[[@R12]\]. However, only a few patients have been reported to have ischemic stroke. The multi-vessel anomaly was documented in several studies \[[@R13]-[@R16]\], but the pathogenesis of cerebral vasculopathy is not clear.

In the current study, we presented a case of ischemic stroke and cerebral vasculitis diagnosed by the radiographic feature of vasculitis pathophysiology using magnetic resonance vessel-wall imaging technique in a female patient with POEMS syndrome. Subsequently, a comprehensive analysis of published literature was undertaken to study the clinical features and pathogenesis of ischemic stroke in POEMS syndrome.

CASE REPORT {#s2}
===========

A 65-year-old female from China was initially admitted to our hospital with a 2-year history of numbness and mild weakness in the distal of low extremities. She experienced chest tightness, cough, fatigue and edema in low extremities for three years with a diagnosis made by a local hospital involving serous pericarditis, multiple lymphadenopathies, bronchiectasis and silent lacunar infarction. She was receiving aspirin, furosemide and spironolactone daily after discharge. She had no relevant family history and medical history of diabetes mellitus, hypertension, hypercholesteremia, alcohol consumption, cigarette smoking and drug abuse. Noteworthy features were found in the review of systems including a 12kg weight loss and pigmentation of skin in the neck, chest, back and limbs during the past two years. The tentative diagnosis of distal symmetrical sensorimotor polyneuropathies was made after nerve conduction studies and the neurological examination on admission. Meanwhile the initial treatment of aspirin, atorvastatin and oral mecobalamin started. On the third hospital day, acute respiratory infection occured, then empirical antibiotics treatment, including penicillin and levofloxacin, was initiated for this patient.

She developed sudden onset of dysarthria and right hemiplegia on the midnight of the seven days after hospitalization. Positive physical examination revealed marasmus, splenomegaly, clubbed-finger, pitting edema in both lower extremities, bilateral papilledema and hyperpigmentation in neck, chest and four limbs. Several nontender enlarged lymph nodes were palpable in the fossa axillary, inguinal area, neck region and left postauricular region. Neurological examination was notable for dysarthria, right hemiplegia with Grade III muscle strength, absent tendon reflexes, and signs of distal symmetrical sensorimotor polyneuropathies in extremities.

Routine laboratory tests, including blood routine, biochemistry test and coagulation function test, were performed and the results were listed in Table [1](#T1){ref-type="table"}. It was noteworthy for moderate anemia (Red blood cell count 3.24×10^12^/L, hemoglobin 85 g/L), thrombocytosis (Platelet count 512×10^9^/L), hyperhomocysteinemia (21.3 umol/L), hypoalbuminemia (35 g/L), hyperuricemia (525 umol/L), hyperfibrinogenemia (5.96 g/L), and increased blood urea nitrogen concentration (12.24 mg/L). Hypersensitive C-reactive protein (Hs-CRP, 15.82 mg/L) was slightly increasing, but the erythrocyte sedimentation rate was normal. Serum tumor marks and autoimmune antibodies were all negative. Serum hormone test was noteworthy for hypothyroidism (Free triiodothyronine (FT3, 1.73 pg/ml), free thyroxine (FT4, 0.78 ng/dl), thyroid stimulating hormone (TSH, 8.3 mIU/L) with negative antibody (thyroglobulin antibody, thyroid peroxidase antibody and thyrotrophin receptor antibody), elevated adrenocorticotropic hormone (ACTH, 150.00 pg/ml) and decreased 24-hours urine free cortisol (81.2 nmol/24h). Glycosylated hemoglobin and oral glucose tolerance test were normal. The opening pressure of cerebrospinal fluid notably increased to 300 mmH~2~O. Cerebrospinal fluid examination demonstrated elevated protein level (1.95 g/L) and elevated IgG level (29.0 mg/dL) with normal cell content, normal concentration of chloride and glucose, and negative oligoclonal band.

###### Summary of laboratory findings in the present case

  --------------------------------------------------------------------------------------------------------------------------------------
  Laboratory tests            Normal/negative   Abnormal finding
  --------------------------- ----------------- ----------------------------------------------------------------------------------------
  Routine blood test                            

   White blood cell count     Normal            

   Red blood cell test                          RBC 3.24×10^12^/L, range: 3.5-5.0×10^12^/L. Hemoglobin 85 g/L, range: 110-150 g/L.\
                                                Hematocrit 0.27, range: 0.37-0.47. MCV 83 fl, range: 80-100 fl.\
                                                MCH 26.1 pg, range: 27-34 pg. MCHC 314 g/L, range: 320-360 g/L.

   Platelet count                               Thrombocytosis ( 512X10^9^/L, range: 100-300×10^9^/L)

   Reticulocytes                                Mile increased (1.6%, range: 0.5-1.5 %)

   Test for anemia                              Mild increased erythropoietin (22.29 IU/L, range: 15-20 IU/L)\
                                                Decreased serum transferrin (120 mg/dL, range: 200-340 mg/dl )\
                                                Decreased serum iron (6.20 μmol/L, range: 9-27 μmol/L )\
                                                Decreased total iron binding capacity (40.8 μmol/L, range: 50-77 μmol/L )

   Hs-CRP                                       Elevated (15.82 mg/L, range: 0-3 mg/L)

   Liver function tests                         Hypoalbuminemia (35 g/L, range: 40-55 g/L)\
                                                Decreased serum prealbumin (112 mg/L, range: 200-400 mg/L )

   Renal function tests                         Increased serum urea nitrogen ( 12.24 mmol/L, range: 2.8-8.2 mmol/L)

   Serum uric acid                              Increased (525 umol/L, range: 90-357 umol/L)

  Plasma homocysteine level                     Hyperhomocystinemia (21.3 umol/L, range: 5-15 umol/L)

  Lipid profile               Normal            

  Troponin T                  Normal            

  Serum folate level                            Decreased (3.39 ng/ml, range: 3.7-19.8 ng/ml)

  Serum Vitamin B12 level                       Decreased (101 pg/ml, range: 180-914 pg/ml)

  ESR                         Normal            

  Antiphospholipid antibody   Negative          

  Serum tumor marks           Negative          

  ANA and ENA antibodies      Negative          

  ANCA antibodies             Negative          

  Complement C3 and C4        Negative          

  ASO and RF                  Negative          

  Coagulation test                              Hyperfibrinogenemia (5.96 g/L, range: 2-4 g/L)

  Serum cystatin C level      Normal            

  Hepatitis panels            Negative          

  HIV antibodies and TPPA     Negative          

  Cerebrospinal fluid                           Increased CSF pressure (300 mmH~2~O, range: 80-180 mmH~2~O)\
                                                Increased protein (1.95 g/L,range: 0-0.4 g/L) and IgG (29 mg/dl, range: 0.4-5.8 mg/dL)

  Oligoclonal band            Negative          

  Thyriod function                              Decreased free T3 (1.73 pg/ml, range: 2.30-4.20 pg/ml)\
                                                Decreased free T4 (0.78 ng/dl, range: 0.90-1.80 ng/dl)\
                                                Increased TSH (8.3 mIU/L, range: 0.55-4.78 mIU/L)

  Anti-thyroid antibodies     Negative          

  Endocrinopathy panels                         Increased ACTH (150.00 pg/ml, range: 7.2-63.3 pg/ml )\
                                                Decreased 24-hours urinary free cortisol (81.2 nmol/24h, range: 129.7-303.6 nmol/L)

  TORCH panels                Negative          

  Serum immunofixation                          IgG kappa monoclonal protein

  Urine immunofixation                          Tiny amount of IgG kappa monoclonal protein

  Serum VEGF                                    Significantly increased (7712 pg/ml, range:100-720 pg/ml)
  --------------------------------------------------------------------------------------------------------------------------------------

MCV: mean corpuscular volume. MCH: mean corpuscular hemoglobin.

MCHC: mean corpuscular hemoglobin contentration.

Serum tumor marks: CEA, AFP, CA125, CA199, CYRFA21-1, SCC, NSE.

ANA: antinuclear antibodies. ENA: extractable nuclear antigen antibodies.

RF: rheumatoid factor. TPPA: treponema pallidum particle agglutination assay.

TSH: thyroid stimulating hormone. ACTH: adrenocorticotropic hormone.

TORCH: Toxoplasmosis, other diseases(including HIV, syphilis, and measles),rubella, cytomegalovirus and herpes simplex.

VEGF: vascular endothelial growth factor.

The nerve conduction study and electromyogram revealed diffuse distal sensorimotor polyneuropathies including both axonal and demyelinating neuropathies. Splenomegaly, lymphadenopathy, moderate ascites were confirmed by sonography. CT scan showed multiple mediastinal lymphadenectasis, right pleural effusion and bronchiectasis in the right middle lobe and left upper lobe (Figure [1](#F1){ref-type="fig"}). No evidence of sclerotic bone lesions was found in whole bone scan. Serum vascular endothelial growth factor was dramatically increasing (7712 pg/mL). To detect monoclonal gammopathy, serum and urine immunofixation electrophoresis were performed. It was noteworthy in serum for an IgG kappa monoclonal protein with increased IgG and free kappa chain (Figure [2](#F2){ref-type="fig"}). The presence of a very tiny amount of IgG kappa monoclonal protein was detected in urine immunofixation.

![CT scan of the thorax showed multiple axillary (Figure [1A](#F1){ref-type="fig"}, green arrow), and mediastinal lymphadenopathy (Figure [1A](#F1){ref-type="fig"}, yellow arrow) in combination with right pleural effusion (Figure [1B](#F1){ref-type="fig"}, white arrow) and pericardial effusion (Figure [1B](#F1){ref-type="fig"}, red arrow)](oncotarget-08-89406-g001){#F1}

![Serum immunofixation electrophoresis revealed an IgG kappa monoclonal protein(Figure [2A](#F2){ref-type="fig"}) with increased IgG and free kappa chain (Figure [2B](#F2){ref-type="fig"})](oncotarget-08-89406-g002){#F2}

The brain magnetic resonance imaging (MRI) was done three days after stroke onset. The diffusion-weighted imaging showed multiple acute infarction lesions in end artery border-zone of the left cerebral hemisphere (Figure [3](#F3){ref-type="fig"}). Transthoracic echocardiography revealed a moderate pulmonary arterial hypertension with a systolic pressure of 53 mmHg and mild pericardial effusion of 4 mm thickness without the presence of abnormal valvular structure and decreased left ventricular ejection fraction. There was no evidence for foramen ovale, atrial myxoma, left atrial appendage thrombus and any aortic pathologies in transesophageal echocardiography. Transcranial doppler, Holter monitoring, and carotid artery ultrasound failed to detect the embolic source. CT angiography showed a great aortic arch and normal artery except diffuse and moderate stenosis in the large vessels from the origin of left internal carotid artery (ICA) to the M1 segment of the left middle cerebral artery (MCA) (Figure [4](#F4){ref-type="fig"}). Strong enhancement of thickened vessel wall in left ICA was observed with high-resolution black-blood gadolinium-enhanced T1-weighted images, suggestive of vasculitis (Figure [5](#F5){ref-type="fig"}).

![Axial DWI sequences showed multiple acute infarction lesions in end artery border-zone of left cerebral hemisphere](oncotarget-08-89406-g003){#F3}

![CT angiography showed a great aortic arch and normal artery (Figure [4A](#F4){ref-type="fig"}) except diffuse and moderate stenosis in the large vessels from the origin of left ICA to the M1 segment of the left MCA (Figure [4B and 4C](#F4){ref-type="fig"}, red arrow)](oncotarget-08-89406-g004){#F4}

![High-resolution T2-weighted imaging showed concentric hyperintensity and thickening in the vessel wall of left ICA and (Figure [5A](#F5){ref-type="fig"}, green circle)\
High-resolution, black-blood MRI before (Figure [5B](#F5){ref-type="fig"}, yellow circle) and after (Figure [6C](#F6){ref-type="fig"}, red circle) gadolinium injection demonstrating a strong, smooth, and concentric vessel wall enhancement in left ICA.](oncotarget-08-89406-g005){#F5}

Multicentric plasma cell variant of Castleman's disease was diagnosed with biopsy of a cervical lymph node (Figure [6](#F6){ref-type="fig"}). Bone marrow biopsy in the back of the pelvic demonstrated slightly increased plasma cell (about 4% of marrow elements) with a small account of atypical cells which were positive for CD3, CD38, CD138, CD79a, CD43, Ki-67 and kappa light chain and negative for CD20 and CD56. But it failed to provide adequate evidence of a definitized myeloma.

![Histological examination of cervical lymph node revealed infiltration of plasma cells in the interfollicular area (original magnification A: ×200, B: ×400)](oncotarget-08-89406-g006){#F6}

We diagnosed her with POEMS syndrome, Castleman's disease and ischemic stroke due to cerebral vasculitis. Since single antiplatelet therapy showed no effect on stopping ischemic recurrence in many previous reports, we changed the initial single antiplatelet therapy into dual antiplatelet therapy with aspirin (100 mg/day) and clopidogrel (75 mg/day) for 14 days, and then switched to aspirin 100 mg/day. After refusing autologous stem cell transplantation, the treatment with mecobalamin (1000 ug/day), dexamethasone (20 mg/day on day 1, 8, 15, and 22 of each 28-day cycle) and thalidomide (100 mg/day in first week, 150 mg/day in second week, then 200 mg/day) was started. The symptoms of dysarthria and right hemiparesis relieved after a week without any side effects of drugs. At a 6-month follow-up, we observed clinical improvement of numbness, weakness, edema and no recurrence of stroke with a reduced VEGF level (1324 pg/L).

LITERATURE SEARCH {#s3}
=================

To retrieve all relevant studies on correlation between POEMS syndrome and ischemic stroke, we conducted a comprehensive search of Pubmed, Web of Science, EMBASE, China National Knowledge Infrastructure (CNKI), Wanfang Database and China Scientific Journal Database (VIP) using the terms "POEMS syndrome" (OR "Crow-Fukase syndrome", "Takatsuki syndrome") and "ischemic stroke" (OR "cerebral infarction", "brain infarction", "brain ischemia", "transient ischemic attack"). The studies including case report and case series published from database inception to February 2017 were included without any language restriction. In addition, articles which didn't have a decomposition of case series into a pattern in which cases could be analyzed individually were excluded, because we should obtain the clinical data such as age, gender, age of stroke onset, initial symptoms, time intervals between stroke onset and POEMS syndrome onset, the location of cerebral infarction, offending vessel, laboratory tests, MRI or CT image, angiography, biopsy, treatment and outcome data from each case. "Symptom improved" was used as good prognosis measure because it was the most common terms used by authors to describe the patient's outcome, while "died" or "deterioration" was used as poor prognosis measure. Every literature was reviewed by two researchers independently.

RESULTS {#s4}
=======

To the best of our knowledge, 24 reports, including three small series and 21 single reports describing 28 cases of POEMS syndrome complicated with ischemic stroke, were identified after exclusion of the reports with incomplete data or duplicate data. All the available data were summarized in Table [2a](#T2a){ref-type="table"}-[2d](#T2d){ref-type="table"} by reviewing the full texts of eligible reports. The comparison of clinical feature in the present study and two previous series was showed in Table [3](#T3){ref-type="table"}.

###### Basic characteristics in patients with POEMS syndrome and ischemic stroke

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Lesprit et al. 1996\       Hori et al. 1999\                 Zhang et al. 2002\                Kang et al. 2003\                             Erro et al. 2003\                                    
                                  \[[@R14]\]                 \[[@R38]\]                        \[[@R39]\]                        \[[@R21]\]                                    \[[@R20]\]                                           
  ------------------------------- -------------------------- --------------------------------- --------------------------------- --------------------------------------------- --------------------------- ------------------------ ------------------------------------------
  Age (years)                     53                         51                                44                                42                                            48                          52                       65

  Sex                             Female                     Female                            Male                              Male                                          Female                      Female                   Female

  Initial symptoms                Organomegaly               Lymphadenopathy                   Skin changes                      N.A.                                          N.A.                        Polyneuropathy           N.A.

  POEMS to Stroke time            24 months                  11 years                          12 months                         N.A.                                          N.A.                        4 months                 29 months

  Symptoms of stroke              Monocular blindness        Aphasia and right hemiplegia      Left hemiplegia                   Dysarthria\                                   Weakness of all limbs       Slurred speech           Right monocular blindness
                                                                                                                                 Right arm monoparesis                                                                              

  Infraction territory            Right ICA territory        Left MCA territory                Right MCA territory               left MCA end BZI\                             Bilateral end artery BZI\   Left MCA/PCA BZI         Right ICA territory
                                                                                                                                 Left MCA/PCA BZI                              Bilateral PCA territory                              

  Cerebral vasculopathy           Right ICA occlusion\       Bilateral ICA occlusion           Right MCA occlusion\              Inceased MFV of left ACA, MCA and right ICA   Left MCA stenosis           Left ICA stenosis        Right ICA occlusion
                                  Left ICA stenosis                                            Diffuse vessels stenosis                                                                                                             

  Vessels evaluation methods      DSA                        DSA                               Ultrasonography                   TCD                                           MRA                         MRA                      MRA

  Extracerebral vasculopathy      SMA and left SA stenosis   N.A.                              \-                                Coronary artery                               Lower extremity artery      N.A.                     Pulmonary artery

  Events (TIA, Stroke)            1                          1                                 1                                 1                                             1                           1                        2

  Risk factors                    \-                         Hypertension                      \-                                Smoking                                       \-                          Hypertension             \-

  Relevant comorbidities          \-                         \-                                \-                                Myocardial infarction                         Left foot gangrene          \-                       Pulmonary embolism

  Medications before stroke       \-                         Cyclophosphamide and prednisone   Dexamethasone                     Aspirin                                       N.A.                        \-                       Oral anticoagulation IVIg and prednisone

  Polyneuropathy                  \+                         \+                                \+                                \+                                            \+                          \+                       \+

  Monoclonal protein              IgA-λ                      IgG-λ                             IgA-λ                             \-                                            \+                          \+                       IgG-λ

  Castleman disease               Not performed              \+                                Not performed                     Not performed                                 \+                          Not performed            Not performed

  Scleroticbone lesions           \+                         \-                                \+                                \-                                            \-                          \-                       \-

  Organomegaly                    Hepatosplenomegaly\        Hepatosplenomegaly\               Hepatomegaly                      Hepatosplenomegaly\                           Hepatomegaly\               \-                       Splenomegaly
                                  Lymphadenopathy            Lymphadenopathy                                                     Lymphadenopathy                               Lymphadenopathy                                      

  Extravascular volume overload   Pleural effussion\         Peripheral edema                  Peripheral edema                  \-                                            Ascites                     Pericardial effusion     \-
                                  Ascites\                                                                                                                                                                                          
                                  Peripheral edema                                                                                                                                                                                  

  Endocrinopathy                  Glucose intolerance        Hypothyroidism\                   Gynaecomastia\                    Hypothyroidism                                Hypothyroidism              Hypothyroidism           Hypothyroidism
                                                             Amenorrhoea                       Hyperprolactinemia                                                                                                                   

  Skin changes                    \+                         \+                                \+                                \+                                            \+                          \+                       \+

  Papilledema                     \-                         \-                                \-                                \-                                            \-                          \-                       \-

  Thrombocytosis                  1000×10^9^/L               \-                                612×10^9^/L                       695×10^9^/L                                   \-                          \-                       560×10^9^/L

  Hyperfibrinogenemia             \-                         \-                                \-                                6.03g/L                                       5.94g/L                     3.61g/L                  \-

  Antibodies                      \-                         \-                                \-                                \-                                            \-                          \-                       \-

  Other abnormalities             Elevated IL-1B             Mild anaemia\                     Polycythemia\                     Elevated CRP                                  Elevated CRP                Elevated CRP\            Elevated CSF protein\
                                                             Elevated CSF protein\             Elevated CSF protein\                                                                                       Pulmonary hypertension   Pulmonary hypertension
                                                             Elevated CSF pressure\            Weight loss (15kg in 12 months)                                                                                                      
                                                             Elevated ESR\                                                                                                                                                          
                                                             Decreased Ccr                                                                                                                                                          

  Stroke treatment                Aspirin and bypass graft   Aspirin                           Aspirin                           N.A.                                          N.A.                        N.A.                     Oral anticoagulation and aspirin

  POMES treatment                 Cyclophosphamide           Melphalan and prednisolone        Dexamethasone                     N.A.                                          N.A.                        N.A.                     Azathioprine and prednisone

  Response to treatment           Deteriorated               Improved                          Deteriorated                      N.A.                                          N.A.                        N.A.                     N.A.

  Survival time                   Died after 2 years         N.A.                              Died 12 months later              N.A.                                          N.A.                        N.A.                     N.A.
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

POEMS to Stroke time: Time from POEMS syndrome onset to stroke onset.

ICA: internal carotid artery. MCA: middle cerebral artery. ACA: anterior cerebral artery. PCA: posterior cerebral artery. BZI: border-zone infarction.

SA: subclavian artery. SMA: superior mesenteric artery.

DSA: digital subtraction angiography. MRA: magnetic resonance angiography. CTA: computed tomography angiography. TCD: transcranial doppler. MFV: mean flow velocity.

Ccr: endogenous creatinine clearance rate. IVIg: Intravenous immune globulin.

N.A.: not available.

###### Basic characteristics in patients with POEMS syndrome and ischemic stroke

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Rolsser et al. 2004\                                                 Wang et al. 2006\                  Garcia et al. 2007\                                                                                   Huang et al. 2007\                                                             Lee et al. 2007\                                Du et al. 2008\                                
                                  \[[@R22]\]                                                           \[[@R30]\]                         \[[@R13]\]                                                                                            \[[@R23]\]                                                                     \[[@R14]\]                                      \[[@R31]\]                                     
  ------------------------------- -------------------------------------------------------------------- ---------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------- ---------------------------------------------- ----------------------------------------------------------------
  Age (years)                     32                                                                   61                                 49                                                                                                    50                                                                             42                                              41                                             65

  Sex                             Female                                                               Male                               Male                                                                                                  Female                                                                         Female                                          Male                                           Female

  Initial symptoms                Edema in limbs                                                       Polyserositis                      Polyneuropathy                                                                                        N.A                                                                            Diarrhea                                        Polyneuropathy                                 Skin changes

  POEMS to Stroke time            6 months                                                             12 months                          24 months                                                                                             12 months                                                                      5 months                                        16 months                                      24 months

  Symptoms of stroke              Right hemiplegia                                                     Left hemiplegia                    Aphasia\                                                                                              Left hemianesthesia                                                            Left hemiplegia Coma                            Dysarthria\                                    Right hemiplegia
                                                                                                                                          Right hemianesthesia                                                                                                                                                                                                                 Left hemiparesis                               

  Infraction territory            Left basal ganglia                                                   Right MCA BZI                      Left MCA end artery                                                                                   Multiple bilateral infractions                                                 Rihgt ICA and Left ACA                          Right MCA territory                            Left MCA BZI

  Cerebral vasculopathy           Left MCA occlusion Left ACA stenosis                                 Normal                             Left MCA occlusion Right MCA and ACA stenosis                                                         Multiple bilateral arteries stenosis                                           N.A.                                            Bilateral MCA stenosis\                        Normal
                                                                                                                                                                                                                                                                                                                                                                               Right ICA stenosis                             

  Vessels evaluation methods      DSA                                                                  Ultrasonography                    DSA                                                                                                   DSA                                                                            N.A.                                            MRA                                            Ultrasonography

  Extracerebral vasculopathy      N.A.                                                                 \-                                 N.A.                                                                                                  Vegetation or thrombus in aortic outflow region                                N.A.                                            SMA stenosis\                                  \-
                                                                                                                                                                                                                                                                                                                                                                               Left renal artery stenosis                     

  Events (TIA, Stroke)            10 TIAs, 2 infractions                                               1                                  2                                                                                                     at least 3                                                                     1                                               1                                              1

  Risk factors                    Hypertension                                                         \-                                 Hypertension Hyperlipidemia                                                                           Hypertension Diabetes, smoking                                                 \-                                              \-                                             \-

  Relevant comorbidities          \-                                                                   \-                                 Ischemic stroke                                                                                       \-                                                                             \-                                              \-                                             \-

  Medications before stroke       Antihypertensive Levothyrocine                                       Diuretic                           Aspirin                                                                                               Aspirin, prednisone\                                                           Antithyroid drugs                               Prednisolone                                   Diuretic
                                                                                                                                                                                                                                                and cyclophosphamide                                                                                                                                                          

  Polyneuropathy                  \+                                                                   \+                                 \+                                                                                                    \+                                                                             \+                                              \+                                             \+

  Monoclonal protein              IgA-λ                                                                IgG-λ                              IgA-λ                                                                                                 IgG-λ                                                                          IgA-κ                                           IgA-λ                                          λ-light chain

  Castleman disease               \+                                                                   Not performed                      \+                                                                                                    \+                                                                             \+                                              \-                                             Not performed

  Scleroticbone lesions           \-                                                                   \+                                 \+                                                                                                    \-                                                                             \-                                              \+                                             \+

  Organomegaly                    Hepatosplenomegaly Lymphadenopathy                                   Splenomegaly Lymphadenopathy       Splenomegaly Lymphadenopathy                                                                          Lymphadenopathy                                                                Hepatosplenomegaly Lymphadenopathy              Hepatosplenomegaly Lymphadenopathy             Splenomegaly Lymphadenopathy

  Extravascular volume overload   Pericardial effusion Pleural effusion Peripheral edema               Pericardial\                       Pericardial\                                                                                          Peripheral edema                                                               Pericardial effusion Ascites Peripheral edema   Ascites\                                       Pericardial effusion Pleural effusion Ascites Peripheral edema
                                                                                                       effusion Pleural\                  effusion Pleural\                                                                                                                                                                                                                    Peripheral edema Pericardial effusion          
                                                                                                       effusion Ascites\                  effusion Ascites                                                                                                                                                                                                                                                                    
                                                                                                       Peripheral edema                                                                                                                                                                                                                                                                                                       

  Endocrinopathy                  Hypothyroidism                                                       Gynaecomastia Hyperprolactinemia   Hypogonadism Hypothyroidism                                                                           \-                                                                             Hyperthyroidism                                 Hypogonadism Hypothyroidism                    \-

  Skin changes                    \+                                                                   \+                                 \+                                                                                                    \+                                                                             \+                                              \+                                             \+

  Papilledema                     \-                                                                   \+                                 \+                                                                                                    \-                                                                             \-                                              \+                                             \+

  Thrombocytosis                  \-                                                                   374×10^9^/L                        \-                                                                                                    \-                                                                             \-                                              511×10^9^/L                                    \-

  Hyperfibrinogenemia             \-                                                                   \-                                 \-                                                                                                    \-                                                                             4.12g/L                                         \-                                             \-

  Antibodies                      \-                                                                   \-                                 ANA 1:160 peckled pattern                                                                             ANA                                                                            \-                                              \-                                             \-

  Other abnormalities             Hyperhomocystinemia Elevated CSF protein                             Elevated CSF Protein\              Elevated CRP and ESR Elevated CSF Protein Vitamin B12 deficiency Elevated VEGF and IL-6 Weight loss   Pancytopenia Hypoalbuminemia Elevated triglycerides Elevated ESR, D-dimer      Hypoalbuminemia Hyperglobulinemia Weight loss   Elevated CRP and ESR Elevated serum creatine   Positive CSF oligoclonal bands
                                                                                                       Positive CSF oligoclonal bands                                                                                                                                                                                                                                                                                         

  Stroke treatment                First heparin Then clopidogrel and phenprocoumon                     Aspirin                            Aspirin                                                                                               Aspirin then clopidogrel                                                       N.A.                                            Anticoagulants (not specified)                 Defibrase,then ozagrel, then aspirin

  POMES treatment                 First prednisone and chlorambucil, then VAD, then cyclophosphamide   Prednisone                         First corticosteroids and rituximab, then dexamethasone and cyclophosphamide                          First Prednisone and cyclophosphamide, then rituximab and methylprednisolone   Dexamethasone                                   Prednisone and melphalan                       Prednisone

  Response to treatment           Improved after cyclophosphamide                                      Deteriorated                       Improved                                                                                              Deteriorated                                                                   Improved                                        Deteriorated                                   Deteriorated

  Survival time                   At least 2 years                                                     Died 6 months later                N.A.                                                                                                  N.A. "gradual deterioration"                                                   N.A.                                            Died 4 weeks later                             Died 6 months later
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

POEMS to Stroke time: Time from POEMS onset to stroke onset.

ICA: internal carotid artery. MCA: middle cerebral artery. ACA: anterior cerebral artery. PCA: posterior cerebral artery. SMA: superior mesenteric artery.

BZI: border-zone infarction. DSA: digital subtraction angiography. MRA: magnetic resonance angiography. TCD: transcranial doppler.

ANA: antinuclear antibody.

VAD: vincristin + doxorubicin + dexamethasone. IVIg: Intravenous immune globulin.

N.A.: not available.

###### Basic characteristics in patients with POEMS syndrome and ischemic stroke

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Zheng et al. 2008\                                               Shi et al. 2010\                                         Jing et al. 2011\                   Sommer et al. 2012\                Dacci et al. 2013\                         Akyol et al. 2014\                          
                                  \[[@R32]\]                                                       \[[@R33]\]                                               \[[@R34]\]                          \[[@R24]\]                         \[[@R25]\]                                 \[[@R15]\]                                  
  ------------------------------- ---------------------------------------------------------------- -------------------------------------------------------- ----------------------------------- ---------------------------------- ------------------------------------------ ------------------------------------------- ----------------------------------------------------------------------------------------------------
  Age (years)                     52                                                               58                                                       40                                  54                                 49                                         46                                          47

  Sex                             Male                                                             Male                                                     Male                                Female                             Male                                       Male                                        Female

  Initial symptoms                Impotence                                                        Polyserositis                                            Skin changes                        Polyneuropathy                     Ischemic stroke                            Ischemic stroke                             Polyneuropathy

  POEMS to Stroke time            3 years                                                          60 months                                                More than 2 years                   2 months                           12 months preceded POEMS onset             1 month preceded POEMS onset                2.5 months

  Symptoms of stroke              Left upper limb palsy                                            Vertigo\                                                 Right hemiplegia                    Right hemiparesis Global aphasia   Aphasia\                                   Left facio-brachial palsy                   Dysarthria\
                                                                                                   Left hemiplegia                                                                                                                 Right hemiparesis                                                                      Right-sided hemiparesis

  Infraction territory            Right MCA territory                                              Right MCA territory                                      Multiple bilateral infractions      Left MCA and left MCA-ACA BZI      Left MCA BZI                               Right PCA BZI                               Bilateral parietal lobes

  Cerebral vasculopathy           Bilateral carotid atherosclerosis                                Normal                                                   Left MCA occlusion                  --                                 --                                         N.A.                                        Left ICA stenosisBilateral MCA occlusion

  Vessels evaluation methods      MRA                                                              Ultrasonography                                          DSA                                 Ultrasonography                    Ultrasonography                            N.A.                                        MRA

  Extracerebral vasculopathy      --                                                               --                                                       --                                  Coronary artery                    N.A.                                       N.A.                                        Pulmonary artery

  Events (TIA,Stroke)             1                                                                1                                                        10                                  2                                  1                                          2                                           4-5 times per day

  Risk factors                    --                                                               --                                                       --                                  Hypertension, diabetes             Smoking                                    --                                          Hypertension, diabetes,hyperlipidemia

  Relevant comorbidities          --                                                               --                                                       --                                  Myocardial infarction              PFO (underwent closure)                    --                                          Hashimoto thyroiditis Pulmonary embolism

  Medications before stroke       Prednisolone                                                     Melphalan and prednisolone                               Aspirin                             Aspirin                            N.A.                                       N.A.                                        Warfarin, aspirin, atorvastatin, gliclazide

  Polyneuropathy                  --                                                               --                                                       --                                  --                                 --                                         --                                          --

  Monoclonal protein              --                                                               IgA-λ                                                    IgG-κ                               IgG-λ                              IgA-λ                                      IgG-λ                                       --

  Castleman disease               Not performed                                                    Not performed                                            --                                  Not performed                      Not performed                              Not performed                               Not performed

  Scleroticbone lesions           --                                                               --                                                       --                                  --                                 --                                         --                                          --

  Organomegaly                    Hepatosplenomegaly                                               Splenomegaly                                             Lymphadenopathy                     Hepatosplenomegaly                 Hepatosplenomegaly                         Splenomegaly                                Hepatosplenomegaly

  Extravascular volume overload   Pleural effusionPeripheral edema                                 Pericardial effusion Pleural effusion Peripheral edema   Pleural effusion Peripheral edema   Pleural effusion                   --                                         Pleural effusion                            Pericardial effusion Peripheral edema

  Endocrinopathy                  Hypothyroidism\                                                  Hyperprolactinemia\                                      Impotence                           Hypothyroidism                     --                                         --                                          Subclinical hypothyroidism
                                  Gynaecomastia\                                                   Low testosterone\                                                                                                                                                                                                      
                                  Low testosterone\                                                Hypercortisolism                                                                                                                                                                                                       
                                  Hyperprolactinemia                                                                                                                                                                                                                                                                      

  Skin changes                    --                                                               --                                                       --                                  --                                 --                                         --                                          --

  Papilledema                     --                                                               --                                                       --                                  --                                 --                                         --                                          --

  Thrombocytosis                  386×10^9^/L                                                      --                                                       --                                  --                                 511x×10^9^/L                               483×10^9^/L                                 687×10^9^/L

  Hyperfibrinogenemia             --                                                               --                                                       6.32g/L                             --                                 --                                         --                                          4.18g/L

  Antibodies                      --                                                               --                                                       --                                  --                                 --                                         --                                          --

  Other abnormalities             Elevated CSF protein Elevated CSF pressure Glucose intolerance   Hyperglobulinemia Hypoalbuminemia\                       Polycythemia\                       Weight loss (10kg)                 Hyperhomocystinemia Elevated CSF Protein   Elevated serum VEGF\                        Orthostatic hypotension Elevated CSF protein Pulmonary hypertension Severe tricuspid regurgitation
                                                                                                   Microalbuminuria                                         Hyperglobulinemia\                                                                                                Elevated CSF protein\                       
                                                                                                                                                            Albuminuria                                                                                                       Elevated CRP andESR                         

  Stroke treatment                Aspirin                                                          N.A.                                                     Aspirin                             Aspirin and clopidogrel            Aspirin                                    Aspirin                                     Warfarin, aspirin, atorvastatin

  POMES treatment                 First prednisone, then prednisone and azathioprine               Melphalan and prednisone                                 Corticosteroids                     Prednisone and radiotherapy        Prednisone and IVIg,then ASCT              First PE and IVIg,then Rev/Dex, then ASCT   Melphalan and prednisone, then cyclophosphamide

  Response to treatment           Deteriorated                                                     Improved                                                 Improved                            Deteriorated                       Improved                                   Improved                                    Deteriorated

  Survival time                   Died 1 year later                                                N.A.                                                     N.A.                                Die 1 day later                    at least 12 months                         at least 6 months                           Sudden cardiac death after two cycles treatment
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

POEMS to Stroke time: Time from POEMS onset to stroke onset.

ICA: internal carotid artery. MCA: middle cerebral artery. ACA: anterior cerebral artery. PCA: posterior cerebral artery. BZI: border-zone infarction.

DSA: digital subtraction angiography. MRA: magnetic resonance angiography.

IVIg: Intravenous immune globulin. ASCT: autologous stem cell transplant. PE:plasma-exchange. Rev/Dex: lenalidomide and dexamethasone.

N.A.: not available.

###### Basic characteristics in patients with POEMS syndrome and ischemic stroke

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                  Yu et al. 2015\                                       Sun et al. 2015\                 Han et al. 2016\                           Rajan et al. 2016\              Yagihi et al. 2016\                                                          Liu et al. 2016\                                  Wang et al. 2016\
                                  \[[@R26]\]                                            \[[@R36]\]                       \[[@R27]\]                                 \[[@R16]\]                      \[[@R28]\]                                                                   \[[@R37]\]                                        \[[@R29]\]
  ------------------------------- ----------------------------------------------------- -------------------------------- ------------------------------------------ ------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------- ----------------------------------------------------
  Age                             24                                                    46                               33                                         36                              32                                                                           37                                                68

  Sex                             Male                                                  Female                           Male                                       Female                          Male                                                                         Male                                              Male

  Initial symptoms                Fever and polyserositis                               Polyneuropathy                   Skin changes and impotence                 Polyneuropathy                  Headaches                                                                    Polyneuropathy                                    Ischemic stroke

  POEMS to Stroke time            2 months                                              9 months                         12 months                                  3 months                        11 months preceded POEMS onset                                               35 months                                         1 month preceded POEMS onset

  Symptoms of stroke              Numbness of the\                                      Acute cognitive impairment       Intermittent amaurosis of left eye         Aphasia\                        Right monocular blindness                                                    Left monocular blindness Right side hemiparesis   Right hemiparesis
                                  upper extremities\                                                                                                                Left facial palsy                                                                                                                                              
                                  Blurred vision                                                                                                                                                                                                                                                                                   

  Infraction territory            First left ventricle,then right ventricle             Bilateral end artery BZI         Left ICA territory                         Left MCA end artery and BZI     RightMCA internal BZI Ophthalmic artery                                      Left MCA BZI and ophthalmic artery                Left MCA-ACA BZI

  Cerebral vasculopathy           N.A.                                                  Right ICA occlusion\             Left ICA occlussion                        Bilateral ICA stenosis\         Right ICA occlusion                                                          Left ICA stenosis                                 Normal
                                                                                        Left ACA stenosis\                                                          Left PCA occlusion                                                                                                                                             
                                                                                        Right ICA stenosis                                                                                                                                                                                                                         

  Vessels evaluation methods      N.A.                                                  MRA                              CTA                                        MRA                             DSA                                                                          MRA                                               CTA

  Extracerebral vasculopathy      --                                                    --                               --                                         --                              Splenic artery                                                               --                                                --

  Events (TIA, Stroke)            At least 4 times                                      1                                1                                          1                               More than 4 times                                                            1                                                 3

  Risk factors                    --                                                    --                               --                                         --                              Smoking                                                                      --                                                --

  Relevant comorbidities          --                                                    --                               --                                         --                              --                                                                           --                                                --

  Medications before stroke       Antitubercular agents                                 Corticosteroids                  --                                         --                              --                                                                           Radiotherapy                                      Aspirin and atorvastatin

  Polyneuropathy                  --                                                    --                               --                                         --                              --                                                                           --                                                --

  Monoclonal protein              --                                                    IgG-λ                            λ-light chain                              IgA-λ                           IgA-λ                                                                        IgG-λ                                             IgA-λ

  Castleman disease               --                                                    Not performed                    --                                         Not performed                   --                                                                           Not performed                                     Not performed

  Scleroticbone lesions           --                                                    --                               --                                         --                              --                                                                           --                                                --

  Organomegaly                    Lymphadenopathy                                       Splenomegaly\                    Splenomegaly Lymphadenopathy               Hepatosplenomegaly              Hepatosplenomegaly Lymphadenopathy                                           --                                                Splenomegaly\
                                                                                        Lymphadenopathy                                                                                                                                                                                                                            Lymphadenopathy

  Extravascular volume overload   Pericardial effusion\                                 Pleural effussion                --                                         Ascites\                        Ascites\                                                                     Pericardial effusion Peripheral edema             Peripheral edema
                                  Pleural effusion\                                                                                                                 Peripheral edema                Peripheral edema Pericardial effusion                                                                                          
                                  Peripheral edema                                                                                                                                                                                                                                                                                 

  Endocrinopathy                  Hypothyroidism\                                       Hypothyroidism                   Hypothyroidism Hyperprolactinemia          --                              Hypothyroidism Hypogonadism\                                                 Gynaecomastia\                                    Hypothyroidism Low testosterone Hyperprolactinemia
                                  Gynecomastia Hypotestosterone\                                                                                                                                    Low testosterone                                                             Impotence Hyperprolactinemia                      
                                  Hyperprolactinemia                                                                                                                                                                                                                                                                               

  Skin changes                    --                                                    \+                               --                                         --                              --                                                                           \+                                                --

  Papilledema                     --                                                    --                               --                                         --                              --                                                                           --                                                --

  Thrombocytosis                  565×10^9^/L                                           427×10^9^/L                      329×10^9^/L                                697×10^9^/L                     700×10^9^/L                                                                  379×10^9^/L                                       452×10^9^/L

  Hyperfibrinogenemia             --                                                    --                               --                                         --                              --                                                                           --                                                --

  Antibodies                      --                                                    --                               --                                         --                              --                                                                           --                                                --

  Other abnormalities             Elevated serum creatine\                              Elevated CRP and ESR\            Polycythemia Hyperuricemia Dyslipidemia\   Polycythemia\                   Elevated CRP and ESR Elevated serum VEGF Elevated CSF Protein Proteinuria\   PolycythemiaLeukocytosis Elevated CRP\            Elevated serum VEGF\
                                  Elevated CSF protein\                                 Elevated serum VEGF\             Hyperphosphatemia Microalbuminuria         Elevated CSF protein            Weight loss                                                                  Elevated CSF Protein                              Elevated ESR Weight loss (3kg in 2 months)
                                  Elevated CSF pressure Weight loss (15kg in 60 days)   Elevated CSF Protein\                                                                                                                                                                                                                      
                                                                                        Weight loss (3kg in 1 month)                                                                                                                                                                                                               

  Stroke treatment                N.A.                                                  Aspirin                          Low molecular heparin                      Antiplatelet drug               Aspirin and verapamil                                                        Aspirin                                           Aspirin, clopidogrel atorvastatin

  POMES treatment                 Lenalidomideand dexamethasone                         Lenalidomide and dexamethasone   Dexamethasone and melphalan                Thalidomide and dexamethasone   Methylprednisolone,then prednisone,then prednisone and cyclophosphamide      First melphalan-based chemotherapy,then ASCT      Melphalan and prednisone

  Response to treatment           Deteriorated                                          Improved                         N.A.                                       N.A.                            Deteriorated                                                                 Improved                                          Improved

  Survival time                   Died two weeks later                                  At least 12 months               At least 6 months                          N.A.                            Died 2 years later                                                           At least 12 months                                At least 24 months
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

POEMS to Stroke time: Time from POEMS onset to stroke onset.

ICA: internal carotid artery. MCA: middle cerebral artery. ACA: anterior cerebral artery. PCA: posterior cerebral artery. BZI: border-zone infarction.

DSA: digital subtraction angiography. MRA: magnetic resonance angiography. CTA: computed tomography angiography.

ASCT: autologous stem cell transplant.

N.A.: not available.

###### Comparison of clinical feature in the present study and two previous series

  ----------------------------------------------------------------------------------------------
  Characteristics                    Present study\   Li \[[@R18]\]\   Dispenzieri \[[@R41]\]\
                                     *N* = 28         *N* = 99         *N* = 99
  ---------------------------------- ---------------- ---------------- -------------------------
  Age (median, years)                47               45               51

  Male sex                           14 (50%)         58 (58%)         62 (62%)

  Initial symptoms                                                     

   Polyneuropathy                    8 (33%)          41 (41%)         N.A.

   Peripheral edema                  1 (4%)           27 (27%)         N.A.

   Skin changes                      4 (19%)          15 (15%)         N.A.

   Serositis                         3 (14%)          4 (4%)           N.A.

   Organomegaly                      2 (10%)          3 (3%)           N.A.

   Ischemic stroke                   4 (19%)          0 (0%)           N.A.

  Polyneuropathy                     28 (100%)        98 (99%)         99 (100%)

   Elevated CSF protein              15 (94%)         69 (96%)         99 (100%)

  Organomegaly                       26 (93%)         85 (86%)         N.A.

   Hepatomegaly                      14 (50%)         47 (47%)         24 (24%)

   Splenomegaly                      21 (75%)         70 (71%)         22 (22%)

   Lymphadenopathy                   17 (61%)         74 (75%)         26 (26%)

  Castleman's Disease                7 (64%)          25 (58%)         11 (73%)

  Endocrinopathy                     23 (82%)         N.A.             73 (74%)

   Thyroid dysfunction               16 (57%)         66 (66%)         26 (26%)

   Impaired glucose metabolism       3 (11%)          21 (21%)         3 (3%)

  Monoclonal plasma cell dyscrasia   25 (89%)         99 (100%)        99 (100%)

   IgA-λ                             10 (40%)         65 (71%)         44 (52%)

   IgG-λ                             8 (32%)          20 (22%)         40 (48%)

   IgM-λ                             0 (0%)           0 (0%)           1 (1%)

   λ                                 2 (8%)           4 (4%)           0 (0%)

   IgG-κ                             1 (4%)           2 (2%)           0 (0%)

   IgA-κ                             1 (4%)           1 (1%)           0 (0%)

  Skin changes                       26 (93%)         89 (90%)         67 (68%)

  Papilledema                        7 (25%)          56 (64%)         29 (29%)

  Extravascular volume overload      24 (86%)         87 (88%)         29 (29%)

   Peripheral edema                  18 (64%)         84 (85%)         24 (24%)

   Pleural effusion                  12 (43%)         43 (43%)         3 (3%)

   Pericardial effusion              12 (43%)         64 (65%)         1 (1%)

   Ascites                           9 (32%)          54 (55%)         7 (7%)

  Sclerotic bone lesions             12 (43%)         19 (19%)         46 (46%)

  Other features                                                       

   Thrombocytosis                    17 (61%)         54 (55%)         53 (54%)

   Polycythemia                      5 (18%)          9 (9%)           18 (18%)

   Hyperfibrinogenemia               6 (21%)          N.A.             N.A.

   Pulmonary hypertension            3 (11%)          36 (36%)         5 (5%)

   Renal impairment                  3 (11%)          37 (37%)         4 (4%)

   Elevated VEGF                     5 (100%)         28(70%)          N.A.

  Surival rate                       8^a^ (44%)       86^b^ (83%)      64^c^ (75%)
  ----------------------------------------------------------------------------------------------

Values are given as number (percent), unless otherwise indicated. The percentages for subcategories are demonstrated as the percentage of patients with the abnormality among those patients who finished the test .

N.A.: not available.

^a^ longest follow-up time of 2 years ^b^ median follow-up time of 26 months

^c^ median follow-up time of 70.6 months

GENERAL CHARACTERISTICS {#s5}
=======================

There were 14 males and 14 females, and the male to female ratio was 1:1. The age of ischemic stroke onset ranged from 24 to 68 years (median age=47 years) without a significant difference between male and female (p=0.303). The median time interval between stroke onset and POEMS syndrome onset was six months. The time interval ranged from 12 months preceded the onset of POEMS syndrome to 11 years after the onset of POEMS syndrome. There were no relevant data in two cases. The data of initial symptom was not documented in 4 cases. The most common initial symptom was polyneuropathy (8, 33.3%). Other initial symptoms included ischemic stroke (4, 16.7%), skin changes (4, 16.7%), polyserositis (3, 12.5%), organomegaly (2, 8.3%), impotence (1, 4.2%), diarrhea (1, 4.2%) and headache (1, 4.2%). Most patients (18, 64.3%) had no risk factors of stroke. Meanwhile, twenty-one patients (75.0%) had not any relevant comorbidities of stroke, only a small proportion of patients complained of hypertension (7, 25.0%), smoking (4, 14.3%), diabetes mellitus (3, 10.7%), hyperlipidemia (2, 7.1%), pulmonary embolism (2, 7.1%), myocardial infarction (1, 3.6%), foot gangrene (1, 3.6%), patent foramen ovale (1, 3.6%), Hashimoto's thyroiditis (1, 3.6%), and previous ischemic stroke (1, 3.6%). Medications before stroke onset which might influence on the risk of ischemic stroke included aspirin (7, 25.0%), glucocorticoids (8, 28.6%) and oral anticoagulants (2, 7.1%).

POEMS FEATURES {#s6}
==============

All the patients had slight to severe symptoms and signs of polyneuropathy. In the 16 patients who were reported to receive lumber puncture, 15 patients (93.8%) had elevated cerebrospinal fluid protein levels. Increasing cerebrospinal fluid opening pressure was observed in 4 patients (25.0%). Abnormal white cell count was not observed in any patient. In addition, oligoclonal bands were positive in 3 patients (15.0%).

Twenty-six patients (92.9%) had organomegaly, in which 14 patients (50.0%) had hepatomegaly, 21 (75.0%) had splenomegaly, and 17 patients (60.7%) had lymphadenopathy. Seven patients (25.0%) had both hepatosplenomegaly and lymphadenopathy. Eleven of these patients underwent lymph node biopsy, four patients (36.4%) of them had normal manifestation and 7 patients (63.6%) had Castleman's disease.

Skin manifestations were observed in 26 patients (92.9%). Hyperpigmentation was the most common manifestation occurring in 23 patients (82.1%), which was followed by skin thickening (8, 28.6%) and hypertrichosis (3, 10.7%). Raynaud's phenomenon occurred in 3 patients (10.7%). In our study, twenty-three patients (82.1%) had at least one recognized endocrinopathy, with thyroid dysfunction (17, 60.7%) as the most common abnormality. Among the patients with thyroid dysfunction, 14 patients (82.3%) needed replacement treatment with high TSH and low serum thyroxine, 2 patients (11.8%) presented with subclinical hypothyroidism while one patient (5.9%) had hyperthyroidism. Hypogonadism (14, 50.0%) was also a common endocrinopathy in patients of POEMS complicated with ischemic stroke. However, only three patients (10.7%) had impaired glucose metabolism.

The evidence of monoclonal plasma proliferative disorder was found in 25 patients (89.3%). The types of monoclonal protein in these patients consisted of IgA-λ (10, 40.0%), IgG-λ (8, 32.0%), λ-light chain alone (2, 8.0%), IgA-κ (1, 4.0%), and IgG-κ (1, 4.0%). The type of monoclonal protein was not reported in 3 patients. Bone marrow aspiration and biopsy were undertaken in a half of patients (50%). Only one patient had \>10% plasma cell.

A variety of patterns of extravascular volume overload was reported in 24 patients (85.7%). Peripheral edema (18, 64.3%) was the most common manifestation in our cases, but pleural effusion (12, 42.9%), pericardial effusion (12, 42.9%) and ascites (9, 32.1%) were also common. In addition, polyserositis was observed in 10 patients (35.7%). Osteosclerotic lesions was documented in 12 patients (42.9%). Papilledema was observed in 7 patients (25%). Eight patients suffered from weight loss and three patients had pulmonary hypertension.

LABORATORY FEATURES {#s7}
===================

Thrombocytosis was a very common manifestation in POEMS patients with ischemic stroke. It was found in 17 patients (60.7%). The abnormal platelet count varied from 329×10^9^/L to 1000×10^9^/L. Polycythemia (5, 17.8%) was more common than anemia (2, 7.1%). Hyperfibrinogenemia was documented in 6 patients (18.5%) while elevated CRP levels in 9 patients (33.3%), elevated ESR in 8 patients (28.3%), hypoalbuminemia in 3 patients (10.7%), renal impairment in 3 patients (10.7%), hyperglobulinemia in 3 patients (10.7%), proteinuria in 3 patients (10.7%) and hyperlipidemia in 2 patients (7.1%). In the five patients who performed the measure of the serum VEGF level, all of them had elevated serum VEGF level. In addition, hyperhomocysteinemia was observed in 2 patients (7.1%). Only two patients had autoantibody abnormality, all of them were antinuclear antibody.

ISCHEMIC STROKE FEATURES {#s8}
========================

Eleven patients (39.3%) experienced more than one event of ischemic stroke. The highest frequency of ischemic attack was more than 4-5 times per day. In our study cohort, multiple ischemic lesions (20, 71.5%) were much more common than single ischemic lesion (8, 28.5%). Evaluation of cerebral arteries was performed by magnetic resonance angiography (9, 36.0%), digital subtraction angiography (7, 25.0%), ultrasonograph (7, 25.0%) and CT angiography (2, 8.0%) in 25 patients. Nineteen patients (76.0%) were found with cerebral vasculopathy while 12 patients (48.0%) had more than one artery involved. It was noteworthy that mismatch between the infarct area and recognized vasculopathy was observed in 8 patients (28.6%). In addition, extracerebral vasculopathy was found in 9 patients (32.1%).

TREATMENT AND OUTCOME {#s9}
=====================

Data of treatment was available in 25 patients (88.9%) of all the patients. Among them, five patients underwent POEMS therapy with melphalan-based chemotherapy, five patients with prednisone or dexamethasone alone, three patients with chemotherapy and autologous stem cell transplantation, two patients with lenalidomide and dexamethasone, one patient with thalidomide and dexamethasone, one patient with cyclophosphamide, one patient with prednisone and percutaneous radiotherapy. Eight patients underwent subsequent treatment due to the poor response to the initial treatment. Data of stroke therapy was available in 22 patients. Among them, 13 patients were treated with single antiplatelet drug (11 cases with aspirin, 1 case with a sequential treatments of aspirin and clopidogrel, 1 case without detail in the report), 2 patients with aspirin and clopidogrel, 2 patients with antiplatelet and anticoagulation therapy (2 cases with aspirin and oral anticoagulation, 1 case with clopidogrel and phenprocoumon) , 2 patients with anticoagulation therapy, 1 patient with a sequential treatment of defibrase, ozagrel and aspirin, 1 patient with aspirin and bypass surgery. Ischemic events were documented in 8 patients even when they were undergoing all the therapy for ischemic stroke, but in 3 cases of them, ischemic attack stopped after the combined treatment for ischemic stroke and POEMS syndrome. Survival data was available in 18 patients with a longest follow-up time of 2 years, ten patients died in total. The comparison of the baseline characteristics of patients with and without fatal outcome was showed in Table [4](#T4){ref-type="table"}. Due to the rare occurrence of ischemic stroke in patients with POEMS syndrome, the sample size was too small to establish any meaningful difference of clinical features between patients with and without fatal outcome. Patients with fatal outcome were older, and more likely to have multiple cerebral vasculopathies, extracerebral pathology, hepatomegaly, hepatosplenomegaly, papilledema, polyendocrinopathy, and extravascular volume overload. Moreover, very few patients in survived group had extracerebral pathology, hepatomegaly hepatosplenomegaly, papilledema, pericardial effusion, ascites and polyserositis.

###### Comparison of clinical features in the patients with and without fatal outcome

  Characteristics                    Death (*N* = 10)   Survived (*N* = 8)
  ---------------------------------- ------------------ --------------------
  Age ( median, years)               52                 46
  Male                               6 (60.0%)          5 (62.5%)
  Multiple ischemic lesions          8 (80.0%)          6 (75%)
  Cerebral vasculopathy              6 (66.7%)          4 (57.1%)
  Multiple cerebral vasculopathies   5 (55.6%)          2 (28.6%)
  Recurrent stroke                   4 (40.0%)          3 (37.5%)
  Extracerebral pathology            5 (50.0%)          1 (12.5%)
  Polyneuropathy                     10 (100%)          8 (100%)
   Elevated CSF protein              6 (60.0%)          4 (50.0%)
  Organomegaly                       10 (100%)          7 (87.5%)
   Hepatomegaly                      7 (70.0%)          1 (12.5%)
   Splenomegaly                      8 (80.0%)          5 (62.5%)
   Lymphadenopathy                   6 (60.0%)          4 (50.0%)
   Hepatosplenomegaly                6 (60.0%)          1 (12.5%)
  Endocrinopathy                     9 (90.0%)          5 (62.5%)
   Thyroid dysfunction               6 (60.0%)          4 (50.0%)
  Polyendocrinopathy                 6 (60.0%)          3 (37.5%)
  Skin changes                       9 (90.0%)          6 (75.0%)
  Papilledema                        6 (60.0%)          0 (0%)
  Extravascular volume overload      10 (100%)          5 (62.5%)
   Peripheral edema                  9 (90.0%)          3 (37.5%)
   Pleural effusion                  6 (60.0%)          2 (25.0%)
   Pericardial effusion              6 (60.0%)          1 (12.5%)
   Ascites                           5 (50.0%)          0 (0%)
   Polyserositis                     6 (60.0%)          0 (0%)
  Sclerotic bone lesions             7 (70.0%)          4 (50.0%)
  Thrombocytosis                     9 (90.0%)          6 (75.0%)
  Hyperfibrinogenemia                1 (10.0%)          0 (0%)

Values are given as number (percent), unless otherwise indicated. The percentages for subcategories are demonstrated as the percentage of patients with the abnormality among those patients who finished the test.

DISCUSSION {#s10}
==========

POEMS syndrome is a rare multi-systemic paraneoplastic disease resulting from an underlying clonal plasma cell disorder, which is characterized by the acronym: polyneuropathy, organomegaly, endocrinopathy, mono-clonal plasma cell disorder, and skin changes \[[@R2]\]. It's also well known to be associated with a myriad of clinical presentations including Castleman's disease, sclerotic bone lesions, pulmonary manifestations, clubbing, weight loss, thrombocytosis, polycythemia, extravascular volume overload and elevated VEGF levels \[[@R1]\]. The pathophysiologic correlates between the myriad of symptoms and the underlying disease have not yet been fully understood, but the correlation has been postulated that cytokines or proangiogenic factors play a pivotal role as mediators \[[@R7]-[@R9], [@R17]\]. Due to its complicated manifestations and atypical initial presentations of POEMS syndrome, misdiagnosis is very common and extensive \[[@R18]\], which is sometimes a major challenge for physicians. Besides the manifestations commonly seen in this syndrome, arterial or venous thrombosis is attracting increasing attention as a less-recognized feature which is suggested to be a predictor of poor prognosis \[[@R8], [@R10], [@R11], [@R14]\]. So far, several cases of ischemic stroke in patients with POEMS syndrome have been reported in the literature \[[@R8], [@R10], [@R12]-[@R15], [@R19]-[@R39]\].

Our patient was a 65-year-old female. She presented polyneuropathy, monoclonal protein, splenomegaly, lymphadenopathy, hypothyroidism, extravascular volume overload (peripheral edema, pericardial effusion, pleural effusion and ascites) and skin changes. She also showed Castleman disease, papilledema, elevated serum VEGF and weight loss. According to the diagnosis criteria recommended by Dispenzieri \[[@R1]\], this patient fulfilled two mandatory major criteria, two other major criteria and six minor criteria. The diagnosis was established after excluding other differential diagnoses. In spite of the absence of traditional and modifiable atherosclerosis risk factors such as diabetes, hypertension, hypercholesteremia or smoking, our patient still developed multiple cerebral infarctions under an adequate secondary stroke prevention therapy including aspirin and atorvastatin. Images of CT angiography showed a diffuse stenosis in the large vessels from the origin of left ICA to the M1 segment of the left MCA which is not likely the result of atherosclerosis but a result of POEMS syndrome. The etiological detection for ischemic stroke (complete blood count, coagulation markers, blood chemistry, serum tumor marks, antiphospholipid antibody, autoimmune antibodies and screen for vasculitis) was unremarkable except for anemia, thrombocytosis, hyperhomocysteinemia and hyperfibrinogenemia. It's noteworthy that thrombocytosis and bone marrow plasmacytosis lead to an increased risk of ischemic stroke in Dupont's study \[[@R12]\]. Thrombocytosis is a well recognized etiologic factor of arterial thrombosis with proposed mechanisms including increased blood viscosity and pre-thromboticstate \[[@R10], [@R40]\]. However, in our study, there are 11 patients (39.3%) with normal platelet counts. Meanwhile, the incidence of thrombocytosis in our cohort consist of POEMS patients with ischemic stroke is very similar to the two large series studies of POEMS performed by Dispenzieri \[[@R41]\] and Li \[[@R18]\] respectively. Most patients in our study just presented mild or moderate thrombocytosis. Only one patient had a platelet count more than 1000×10^9^/L. In contrast, most studies agreed that platelet count apparently did not correlate with the risk of thrombosis in patients with essential thrombocythemia except the patients with the basis of age above 60 years, cardiovascular risk factors, thrombosis history and the presence of JAK-2 mutation \[[@R42], [@R43]\]. Even a very high platelet count is associated with a high risk of bleeding but not thrombosis \[[@R43]\]. Also, it is very rare that myeloproliferative and plasma cell proliferation develop in the same patient. It's postulated that abnormal cytokine hyperproduction such as interleukin-6 (IL-6) and interleukin-1 (IL-1) may be responsible for the muti-systematic manifestations including thrombocytosis and Castleman's disease \[[@R44]\]. In addition, the recurrence of ischemic stroke was observed in 8 patients even under sufficient oral antiplatelet therapy, which indicated a complex association between POEMS syndrome and ischemic stroke.

Recently, fibrinogen is emerging as an independent risk factor for cardiovascular diseases and peripheral vascular diseases. However, still few studies are available to regard the role of fibrinogen in the pathogenesis of ischemic stroke. Previous studies have shown conflicting results as to whether fibrinogen is a predictor for risk of ischemic stroke \[[@R45], [@R46]\]. Kang and colleagues found all of their three cases had elevated fibrinogen levels \[[@R21]\]. The phenomenon was also observed in a patient with a large area of cerebral infarction and Castleman's disease reported by Huang et al \[[@R23]\]. They suggested IL-6 inducing hyperfibrinogenemia might act a pivotal part as a trigger of procoagulatory in the development of stroke in patients with POEMS syndrome \[[@R15], [@R21], [@R23], [@R34]\]. Fibrinogen is a predictor of wide-spread inflammation process and also frequently elevated before the cerebrovascular events in the patients without a history of POEMS, because cytokines such as IL-1, IL-6 and tumor necrosis factor which were demonstrated to be elevated in patients with POEMS syndrome, can also be produced by atherosclerosis macrophages \[[@R47], [@R48], [@R49]\]. Moreover, hyperfibrinogenemia is not observed in all patients with elevated cytokine levels. In addition, there were only six patients (21.2%) had elevated fibrinogen levels in our review. From the standpoint of available evidence, the hypothesis of the pivotal role of fibrinogen in the etiologic link between the two disorders is less plausible.

On the other hand, hyperhomocysteinemia was observed in our case and two patients (7.1%) in our review, which may be a critical but often-neglected component of POEMS. Numerous studies have demonstrated that hyperhomocysteinemia is a strong and independent risk factor for ischemic stroke \[[@R49], [@R50]\]. It is now well recognized that vitamin B12 supplement therapy can reduce homocysteine levels, which will lead to a reduced risk of ischemic stroke \[[@R50]\]. Recently, vitamin B12 deficiency unresponsive to replacement therapy has been recognized as a less common manifestation of POEMS \[[@R3], [@R4]\]. Although our patient received a sufficient treatment of oral mecobalamin 500ug three times a day, we still detected a low vitamin B12 value and hyperhomocysteinemia without the presence of intrinsic factor antibodies. The pathophysiological mechanisms under vitamin B12 deficiency and hyperhomocysteinemia in POEMS syndrome worth exploring. This phenomenon may be caused by the abnormal uptake in gastric mucosa which may suffer from microangiopathy and vasopermeability induced by VEGF.

Vessel endothelial cell is an important target of cytokines and M protein \[[@R8], [@R10], [@R17], [@R51], [@R52]\]. It's noteworthy that large artery occlusive disease in our study is much more common than that reported in stroke registry studies \[[@R53], [@R54], [@R55]\]. However, the frequencies of stroke risk factors such as diabetes mellitus, hypertension and atrial fibrillation occurred in our study are similar to or even lower than those in stroke registries \[[@R54], [@R55]\]. In accordance with previous literature, the preponderance of multiple cerebral vessel lesions and coexistence of extracerebral vessel disease in patients of POEMS without stroke risk factors are also more common than those reported in stroke registries \[[@R13]-[@R14], [@R22]-[@R24], [@R27]-[@R28], [@R38]\]. This phenomenon may suggest that POEMS syndrome has a predisposition towards large-vessel vasculopathy which could only be confirmed by biopsy. To the best of our knowledge, pathologically confirmed cerebral vasculopathy has not been reported yet. Conventional angiographic findings of cerebral vasculopathy are nonspecific and can't reliably distinguish vasculopathy from atherosclerosis \[[@R56]\]. Magnetic resonance vessel-wall imaging is the most promising technique for differentiating between vasculopathy and atherosclerotic disease \[[@R56]\]. Our patient showed a thickening and enhancement of the vessel wall of the left ICA, indicative of vasculitis. In the previous studies, a noninflammatory vasculopathy, which is speculated to be the pathogeny of stroke according to the benign cerebrospinal fluid manifestation in patients \[[@R12], [@R28]\], might be due to proangiogenic factors including VEGF. However, the hypothesis is challenged in the absence of pathological evidence \[[@R12], [@R28]\]. There is growing evidence that endothelial dysfunction plays an important role in the pathogenesis of POEMS syndrome. Moreover, pathologically confirmed vasculitis involving small-sized and medium-sized muscular artery are reported to be directly associated with POEMS syndrome \[[@R57], [@R58]\]. In addition, larger-sized vessels are also suspected to be affected in POEMS syndrome \[[@R8], [@R10], [@R22], [@R59]\]. Co-existing quasi-moyamoya disease and POEMS syndrome were observed in a patient with sudden-onset intracranial hemorrhage \[[@R60]\]. Progressive intracranial large-vessel vasculopathy has been reported as the initial presenting manifestation of POEMS \[[@R28]\].

The precise pathophysiological mechanism of the development of cerebral vasculopathy remains unknown. An correlation with cerebral vasculopathy and Castleman's disease in patients with POEMS syndrome was reported in several studies. Castleman's disease is one of the major criteria for the diagnosis of POEMS syndrome \[[@R1]\]. An association with Castleman's disease was reported in nearly half of patients with POEMS syndrome. However, the pathogenesis of Castleman's disease remains unclear. A complex cytokine and chemokine network, including VEGF, IL-6, and IL-1, may play an important role in the development of Castleman's disease \[[@R61]\]. Also, the network may induce a systemic inflammatory condition which may lead to cerebral vasculopathy and ischemic stroke \[[@R62]\]. Ischemic stroke is the most common manifestation of cerebrovascular involvements of Castleman's disease. Seven patients were found with Castleman's disease and ischemic stroke in our study. In the five patients who had undergone an evaluation of cerebral vessels, all of them were found with cerebral vascopathy. It indicated that there was a strong association between cerebral vasculopathy and Castleman's disease. Hori et al. \[[@R38]\] described a patient with Castleman's disease and POEMS syndrome who presented hypertrophic cranial pachymeningitis and bilateral internal carotid artery occlusion due to suspected vasculitis. Rössler and colleague \[[@R22]\] reported a patient with Castleman's disease and POEMS syndrome who presented recurrent ischemic stroke secondary to clinical diagnosed cerebral vasculitis. Garcia et al. \[[@R13]\] described two patients with diffuse stenosis of the intracranial arteries, being suggestive of a non-atherosclerotic cerebral vasculopathy. They hypothesized that cerebral vascopathy might be caused by the overproduction of cytokines, such as VEGF, IL-6, and IL-1. Elevating serum levels of IL-6 is very common in patients with Castleman's disease \[[@R61]\], and it's well known as a key factor of the systemic inflammatory and a predictor of poor outcome of ischemic stroke \[[@R62]\]. IL-6 may play a pivotal role in the etiologic link between Castleman's disease and the occurrence of cerebral vascopathy and ischemic stroke.

Recently, the overproduction of VEGF has been proved to contribute to most of the clinical manifestations and correlate with the disease activity and response to therapy \[[@R5], [@R6]\]. Meanwhile, VEGF is also suggested to be the key factor of vessel walls damage in POEMS syndrome. VEGF is a potent multifunctional cytokine that potently induces angiogenesis, microvascular hyperpermeability and inflammation on vascular endothelial cells \[[@R63], [@R64]\]. Elevated serum or plasma VEGF, as one of the major diagnostic criteria of POEMS syndrome, induces plasma exudation and the migration of inflammatory cells into vascular inflammatory lesions via upregulating the expression of procoagulative properties, endothelial adhesion molecules and leukocyte chemokine, which in turns initiate and aggravate endothelial damage \[[@R65]\]. Angiogenesis within the adventitia of vessel walls induced by VEGF, which also plays an important role in the pathogenic of chronic inflammation of vessel walls \[[@R7], [@R8], [@R64]\]. The histopathological findings of high VEGF expression on arterial smooth muscle cells may result from the high level of VEGF. On the other hand, the elevated VEGF may be produced not only by VEGF secreted from plasma cells and platelets but also by VEGF exudation from inflamed organs including vessels \[[@R63]\]. In this context, VEGF is suggested to be an important mediator in the development of multiple vasculopathy lesions, and this hypothesis is strengthened by the phenomenon that increased VEGF has been observed in many vasculitic disorders include Takayasu's arteritis and Behcet's disease \[[@R66]\].

POEMS syndrome is considered as a chronic disease with a good long-term outcome. Recent data demonstrated that 5-year and 10-years survival rate was 84% and 77%, respectively \[[@R67]\]. It's documented that only age more than 50 years, pulmonary hypertension, pleural effusion and an eGFR less than 30 ml/min/1.73 m^2^ were independently associated with overall survival \[[@R67]\]. In contrast, we observed fatal outcome in POEMS patients complicated with ischemic stroke. Ten of the eighteen patients who had follow-up data died within two years after stroke events. Even most of them had already received sufficient therapies for ischemic stroke and POEMS syndrome \[[@R10], [@R14], [@R15], [@R24], [@R26], [@R28]\]. It suggested that ischemic stroke was a poor outcome predictor in patients with POEMS syndrome. But until now, there is a lack of evidence and standard of the appropriate treatment for the patients who suffer from POEMS syndrome and ischemic stroke simultaneously. The recommended treatments for POEMS syndrome include autologous stem cell transplantation, radiotherapy and melphalan-based chemotherapy \[[@R1]\]. It is worth noting that recurrent ischemic stroke events were interrupted after chemotherapy or corticosteroids therapy in several patients \[[@R12], [@R25], [@R27]\]. Immunomodulatory drugs including thalidomide and lenalidomide represent a new treatment option for the patients with POEMS syndrome, not only because of their excellent suppression of monoclonal plasma cell proliferation, but also because of the modulation of VEGF secretion and upregulated cytokines suppressed by these drugs \[[@R1], [@R5], [@R6], [@R68]\]. Meanwhile, VEGF inhibition is currently studied in cardiovascular disease \[[@R69]\] and has also shown neuroprotective effects on cerebral ischemia and reperfusion injury \[[@R70]\]. They have been considered for cerebrovascular disease. Single antiplatelet therapy including aspirin and clopidogrel, as a recommendation of AHA/ASA guideline for stroke secondary prevention \[[@R54]\], showed no effect on stopping ischemic recurrence in many reports \[[@R13], [@R15], [@R20], [@R21], [@R24], [@R29]\]. Meanwhile, recurrent events were observed under heparinization or oral anticoagulation \[[@R15], [@R20], [@R22]\]. So more aggressive therapy is required. Dual antiplatelet therapy with clopidogrel and aspirin may be a potential treatment, which was reported in some studies \[[@R24], [@R29]\]. Even though there is an increased incidence of hemorrhage using combination therapy with clopidogrel and aspirin, the risk of ischemic events is markedly reduced in predisposed patients with no response to initial antithrombotic therapy treatment or with established atherothrombotic disease. Despite these advances, the management of POEMS syndrome remains a major challenge, especially in the patients complicated with ischemic stroke.

LIMITATIONS {#s11}
===========

Ischemic stroke is a less common manifestation of a rare disease-POEMS syndrome. As a result of the lack of understanding of the association between ischemic stroke and POEMS syndrome, many cases have been misdiagnosed. There have been just a few reports on this disease and most of them are case reports. Also, details were not provided in some of the cases, including vascular imaging data, recurrent event data and survival data. The extremely rare occurrence of ischemic stroke in patients with POEMS syndrome and a comprehensive analysis of literature primarily based on cases reports present challenges in establishing any firm conclusions on pathogenesis, management and prognosis. Further research focusing on larger cohort may help in better characterizing and treating this rare complication of POEMS syndrome.

CONCLUSION {#s12}
==========

To the best of our knowledge, the present case of POEMS syndrome is the first to describe to be associated with cerebral vasculitis confirmed by magnetic resonance vessel-wall imaging technique. The underlying cerebral vasculopathy, leading to the occurrence of ischemic stroke, may be induced by the overproduction of cytokines and systemic inflammation due to POEMS syndrome. Magnetic resonance vessel-wall imaging technique, which is the most promising noninvasive technique for differentiating cerebral vasculopathy from atherosclerotic disease, may contribute to an early diagnosis and treatment for patients with POEMS syndrome. Our literature analysis has revealed that ischemic stroke is a poor outcome predictor in patients with POEMS syndrome. A preponderance of multiple cerebral vessel lesions and low survival rate were observed. VEGF may play a critical role in the pathogenesis of POEMS syndrome. It's also an important mediator in the development of cerebral vasculopathy. Carefully studying ischemic stroke in patients with POEMS syndrome might help to improve the survival rate and the prognosis.
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